VIMOVO
Land: Israel
Sprog: engelsk
Kilde: Ministry of Health
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE 20 MG; NAPROXEN 500 MG
Tilgængelig fra:
ASTRA ZENECA ISRAEL LTD
ATC-kode:
G02CC02
Lægemiddelform:
TABLETS MODIFIED RELEASE
Indgivelsesvej:
PER OS
Fremstillet af:
ASTRA ZENECA AB., SWEDEN
Terapeutisk gruppe:
NAPROXEN
Terapeutiske indikationer:
Vimovo is a combination product that contains naproxen and esomeprazole. It is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.
Autorisation dato:
2011-12-01
